At Grant Engine, we remain vigilent and focused on our mission of saving lives through improving the standard of care for patients in areas of unmet clinical need.

While this crisis has impacted all of us, we are channeling our focus to re-double our efforts for our clients both existing and new.

Please see the FDA guidance on Coronavirus Treatment Acceleration Program.

Below, please see latest opportunities.  Stay tuned for updates!

AFWERX: Combating the Spread; Welfare of citizens; Readiness; Logistics; Industrial base impact; Medical; others.

DARPA: Standard SBIR programs available.

Sponsor Link First Available Due Date(s) Expiration Date Notes
BARDA https://beta.sam.gov/opp/1b46a4169fcb4902b9c4fcbb5bf981f7/view 4/30/20 10/31/20
CDC https://beta.sam.gov/opp/728e1131ef444abc880f63540a37c364/view?keywords=COVID-19&sort=-relevance&index=&is_active=true&page=2 3/25/20 4/9/20
NIAID https://beta.sam.gov/opp/8476add0be544073a56f97ec196608ba/view?index=opp&naics=541&page=6 4/9/20 6/30/21
NIH https://grants.nih.gov/grants/guide/notice-files/NOT-AI-20-030.html 2/6/20 2/6/21 rolling basis
NIH https://grants.nih.gov/grants/guide/rfa-files/RFA-AI-20-028.html 6/29/20 6/30/20
NIH https://grants.nih.gov/grants/guide/pa-files/PAR-18-781.html 9/9/20 9/10/20
NIH https://grants.nih.gov/grants/guide/notice-files/NOT-DA-20-047.html 3/19/20 3/31/21 supplement to existing awards.
NIH https://grants.nih.gov/grants/guide/notice-files/NOT-HL-20-757.html 3/17/20 10/6/20
NIH https://grants.nih.gov/grants/guide/pa-files/PA-18-935.html continuous submission
NIH https://grants.nih.gov/grants/guide/pa-files/PAR-20-139.html 5/13/20 1/14/23
NIHR https://www.nihr.ac.uk/documents/travel-and-subsistence-funding-to-support-lmic-engagement-during-the-covid-19-outbreak-guidance/24356 5/30/20 continuous submission
NSF https://www.nsf.gov/pubs/2020/nsf20055/nsf20055.jsp

COVID-19 specific: https://www.nsf.gov/pubs/2020/nsf20065/nsf20065.jsp

30 March 2020 Webinar highlights: NSF Webinar on COVID.

Before submitting a RAPID proposal or supplemental funding request in response to this DCL, investigators must first contact one of the cognizant OAC program officers listed
NSF https://www.nsf.gov/pubs/2020/nsf20052/nsf20052.jsp check with Grant Engine to access PO
https://beta.sam.gov/opp/53badf9fb02349e78839a541495efc6a/view 4/15/20 4/30/20
https://research.utexas.edu/find-funding/open-call-grant-opportunities/ University of Texas link to Covid-19 related funding opportunities
HHS RFI: Priority ICU Medicines COVID-19 https://beta.sam.gov/opp/f32a1c52a3ba4a05a321163c1fd96811/view
Also see these two organizations.  Both of these are Department of Defense Other Transactional Authority consortia and are waiving the membership requirement for membership.  If selected, you have to become a member.  These two groups are looking to get money out the door quickly.
MTEC

The Medical Technology Enterprise Consortium (MTEC) is excited to post this announcement for a Request for Project Proposals (RPP) focused on the development of prototypes aimed to treat COVID-19 with the following focus area:

FOCUS AREA: Therapeutic(s) that can treat COVID-19.  Treatments with potential application to the prevention of COVID-19 infection are desired.  Therapeutics that can be administered in a non-hospital environment are desired.

PROGRAM BACKGROUND:

The pandemic COVID-19, a disease caused by a novel coronavirus, continues to spread worldwide. As of March 25, 414,467 confirmed cases of COVID-19 have been reported worldwide, with 18,433 deaths from the disease (www.who.int), the total number of COVID-19 cases in the United States is 55,453 and total number of deaths is 737 (www.cdc.gov). Currently, there are currently no FDA-approved vaccines or treatments for COVID-19.

SOLUTION REQUIREMENTS:

The goal of this RPP is to develop prototype countermeasures for the treatment of COVID-19.

  • The expected technology readiness level (TRL) at start of the period of performance (POP) is 3/4 and at the end of the POP is TRL6 [TRL definitions: mtec-sc.org/wp-content/uploads/2016/12/TRL-definitions.pdf]
  • The Offeror is expected to have, at the onset, a candidate therapeutic with non-clinical data (in vitro, tox, pre-clinical data, etc.) suggesting safety and/or efficacy
  • The Offeror should have demonstrated manufacturing feasibility of the candidate therapeutic
  • Offerors who have had at least one meeting with the FDA to discuss the regulatory strategy for their candidate(s) are preferred
  • Repurposing commercially available, approved products or products in clinical development for related indications with demonstrated safety in humans are preferred
  • Partnering with DoD investigators on pre-clinical testing in animal models is encouraged, where appropriate. [Note: Relationships with DoD laboratories must be brought forth as part of the Enhanced White Paper. MTEC members can access points of contact at Army laboratories on the members-only website.]

The expected deliverable at the end of the POP is a final technical report to support a Go/No go decision for the product to enter Phase II trials for the treatment of COVID-19 (see RPP for more details).

There is potential for award of one or more follow-on tasks based on the success of any resultant Research Project Awards (subject to change depending upon Government review of work completed). Note that any potential follow on work is expected to be awarded non-competitively to resultant project awardees:

  • Manufacturing of therapeutics
  • Further clinical testing of therapeuticsPOTENTIAL FUNDING AVAILABILITY:The U.S. Government (USG) Department of Defense (DoD) currently has available approximately $20 Million (M) of FY20 funds. Any potential follow-on funding is expected to be awarded non-competitively and negotiated based on outcomes, cost sharing, partner matching and estimates for additional study completion.The anticipated Period of Performance (PoP) is up to 8 months. Dependent on the results and deliverables, additional time may be added to the period of performance for follow-on tasks.It is expected that MTEC will make up to 5 awards to qualified teams to accomplish the statement of work.

Enhanced White Paper Profile here. To view this solicitation, click here.

NOTICE OF SPECIAL INTERESTS AT NIH

 

NOT-AI-20-034 Notice of Special Interest (NOSI) regarding the Availability of Emergency Competitive Revisions for Research on Severe Acute Respiratory Syndrome National Institute of Allergy and Infectious Diseases (NIAID)
NOT-AI-20-040 Notice of Early Expiration of “Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on the 2019 National Institute of Allergy and Infectious Diseases (NIAID)
NOT-GM-20-025 Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on Coronavirus Disease 2019 (COVID-19) National Institute of General Medical Sciences (NIGMS)
NOT-AI-20-030 Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus (2019-nCoV) National Institute of Allergy and Infectious Diseases (NIAID)

National Institute of General Medical Sciences (NIGMS)

NOT-HL-20-757 Notice of Special Interest (NOSI): Availability of Administrative Supplements and Revision Supplements on Coronavirus Disease 2019 (COVID-19) National Heart, Lung, and Blood Institute (NHLBI)
NOT-DA-20-047 Notice of Special Interest (NOSI) regarding the Availability of Administrative Supplements and Urgent Competitive Revisions for Research on the 2019 Novel Coronavirus National Institute on Drug Abuse (NIDA)
NOT-TR-20-011 Notice of Special Interest (NOSI) Clinical and Translational Science Award (CTSA) Program Applications to Address 2019 Novel Coronavirus (COVID-19) Public Health Need National Center for Advancing Translational Sciences (NCATS)
NOT-GM-20-025 Notice of Special Interest (NOSI) regarding the Availability of Urgent Competitive Revisions for Research on Coronavirus Disease 2019 (COVID-19) and the Causative Virus SARS-CoV-2 National Institute of General Medical Sciences (NIGMS)

 

 As always, feel free to reach us directly on (650) 937-9164 and sam@grantengine.com.